EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 16.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,199,056 shares of the company’s stock after buying an additional 166,699 shares during the period. Geode Capital Management LLC’s holdings in EyePoint Pharmaceuticals were worth $9,583,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in shares of EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after acquiring an additional 4,172 shares during the period. Greenwich Wealth Management LLC acquired a new position in EyePoint Pharmaceuticals during the 2nd quarter worth $94,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in EyePoint Pharmaceuticals by 271.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company’s stock worth $95,000 after purchasing an additional 7,953 shares in the last quarter. Cyndeo Wealth Partners LLC purchased a new stake in EyePoint Pharmaceuticals during the 3rd quarter worth about $100,000. Finally, Arizona State Retirement System raised its position in EyePoint Pharmaceuticals by 9.7% in the 2nd quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after purchasing an additional 1,171 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on EYPT. Chardan Capital boosted their price objective on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Scotiabank started coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price objective on the stock. Robert W. Baird lowered their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research note on Monday, November 11th. Finally, StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.71.

EyePoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $7.45 on Thursday. The firm’s fifty day moving average price is $9.17 and its 200 day moving average price is $8.98. EyePoint Pharmaceuticals, Inc. has a 12 month low of $6.90 and a 12 month high of $30.99. The company has a market capitalization of $508.47 million, a price-to-earnings ratio of -3.73 and a beta of 1.45.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.